- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04466098
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)
Study Overview
Status
Intervention / Treatment
Detailed Description
MSCs are adult, non-hematopoietic precursor cells derived from a variety of tissues (e.g., bone marrow, adipose tissue, and placenta) and have been used as therapy in multiple conditions, especially in immune-mediated inflammatory diseases, such as graft versus-host disease (GVHD) and systemic lupus erythematosus (SLE) with evidence of benefit.
In preclinical models, MSC are effective in ameliorating acute lung injury due to their ability to secrete paracrine factors that regulate lung endothelial and epithelial permeability, including growth factors, anti-inflammatory cytokines, and antimicrobial peptides. Based on the promising pre-clinical preliminary data and intriguing results in patients with COVID-19 associated pneumonia and ARDS as well as an established safety profile of MSC generally and in ARDS in particular, the researchers propose multiple dosing of MSCs as a study treatment to ameliorate the severity and duration of SARS-CoV-2 associated pneumonia and ARDS potentially improve survival.
Patients will receive study agent (MSC or placebo) within 48 hours of enrollment. Three doses will be administered unless a severe infusion adverse event occurs that is related to the MSC infusion. Doses will be repeated approximately every 48-72 hours with the aim of completing 3 doses within 7 days of the first dose. All patients will receive standard of care treatments for ARDS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15261
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-80 years
- Meets 'Berlin Criteria' for diagnosis of moderate to severe ARDS for a minimum of 4 hours
- Less than 48 hours on a ventilator after meeting criteria for diagnosis of ARDS
- SARS-CoV-2 (proven by RT-PCR assay) with radiographic infiltrates
- PaO2/FiO2 < 250
- Positive end-expiratory airway pressure (PEEP) >5 cm H20
- Elevated C-reactive protein (above laboratory upper limit of normal)
- Meets organ function requirements, including left ventricular ejection fraction (LVEF) >35% ( as defined below)
- Off other investigational agents directed against inflammatory cytokines 48 hours prior to enrollment; agents directed against the replication of SARS-CoV-2 [e.g., Remdesivir] are permitted
- Voluntary informed consent in person or virtually by the patient or patient surrogate considering the face to face limitations during the COVID-19 pandemic and, given the nature of the study population, which frequently requires mechanical ventilation with sedation, surrogate consent will likely occur in a substantial proportion of the study population (this will remain a valid consent until the patient is fully alert, and aware, and can provide a second consent to continue participation in the study).
Adequate organ function is defined as:
- Renal: Calculated estimated glomerular filtration rate >30 mL/min/1.73 m2 (on chemistry panel)
- Hepatic: Bilirubin <3x upper limit of normal (ULN) and AST, ALT and alkaline phosphatase <5x ULN
- Cardiac: Absence of uncontrolled arrhythmia and LVEF >35%
Exclusion Criteria:
Ventilator support of FiO2 >0·8 or PEEP >20 cm H2O and ongoing use of more than two vasopressors for 2 or more hours with any agent at doses shown below in the supine position.
- Norepinephrine >12 μg/min or 0.2 μg/kg per min
- Phenylephrine >150 μg/min or 3 μg/kg per min
- Epinephrine >10 ug/min or 0.2 μg/kg per min
- Vasopressin >0.04 units/min
- Concurrent use of other investigational agents specifically for treatment of ARDS or inflammatory cytokines. (Note: Agents established to be efficacious and/or those used outside of formal trials are permitted as supportive data emerge)
- Known ineligibility for use of a ventilator for a minimum of 7 days, as judged by the institution's Triage Team
- Known allergy to MSC components: fetal calf serum, human albumin or DMSO
- Active invasive malignant disease requiring chemotherapy/radiation
- Other concurrent life-threatening disease (life expectancy <6 months) or eligible for hospice care
- Known history of HIV infection on active treatment
- Females who are pregnant or breastfeeding
- Current mean arterial pressure (MAP) <60 mmHg while on 2 or more vasopressors at above doses for more than 2 hours
- History of any significant cardiac (myocardial infarction within 12 months of screening visit or unstable angina), chronic ongoing hepatic, or renal disease (grade 3 or higher); diagnosis of congestive heart failure with hypoxemia primarily due to decompensated heart failure; diagnosis of severe chronic obstructive pulmonary disease (COPD) or interstitial lung disease requiring supplemental oxygen at home
- Concurrent diagnosis of diffuse alveolar hemorrhage
- Requiring continuous dialysis (unable to stop dialysis during study agent infusion)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Mesenchymal Stromal Cells
Three fixed doses of MSC approximately 48 hours apart.
|
Thawed product containing MSC(300x10^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin [total volume 60 mL]
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Three fixed doses of placebo control approximately 48 hours apart.
|
Dextran 40 + 5% human serum albumin [total volume 60 mL]
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC
Time Frame: Within 6 hours of the start of the infusion
|
Within 6 hours of the start of the infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of a reduction in one or more biomarkers of inflammation by day 7
Time Frame: Day 7 after first infusion
|
Day 7 after first infusion
|
|
Trend changes in PaO2:FiO2 ratio
Time Frame: On the day of screening and on days 3, 7 and 14 after first infusion
|
On the day of screening and on days 3, 7 and 14 after first infusion
|
|
Trend changes in Mean Airway Pressure
Time Frame: On the day of screening and on days 3, 7 and 14 after first infusion
|
On the day of screening and on days 3, 7 and 14 after first infusion
|
|
Trend changes in peak pressure
Time Frame: On the day of screening and on days 3, 7 and 14 after first infusion
|
On the day of screening and on days 3, 7 and 14 after first infusion
|
|
Trend changes in plateau pressure
Time Frame: On the day of screening (baseline) and on days 3, 7 and 14 after first infusion
|
On the day of screening (baseline) and on days 3, 7 and 14 after first infusion
|
|
Trend changes in Positive end-expiratory airway pressure (PEEP)
Time Frame: On the day of screening and on days 3, 7 and 14 after first infusion
|
On the day of screening and on days 3, 7 and 14 after first infusion
|
|
Incidence of mortality
Time Frame: 28 days after first infusion
|
28 days after first infusion
|
|
Incidence of mortality
Time Frame: 100 days after first infusion
|
100 days after first infusion
|
|
Number of ICU-free days
Time Frame: 28 days after first infusion
|
28 days after first infusion
|
|
Number of days alive and ventilator free composite score 3
Time Frame: 28 days after first infusion
|
28 days after first infusion
|
|
Change in acute lung injury (ALI) score 2
Time Frame: Baseline and Day 28 after first infusion
|
Acute Lung Injury Score is a composite 4 point scoring system validated by the NHLBI ARDS Network that considers PaO2/FiO2, the level of positive end-expiratory airway pressure, respiratory compliance, and the extent of pulmonary infiltrates on the chest radiograph
|
Baseline and Day 28 after first infusion
|
Incidence of serious adverse events
Time Frame: 28 days after first infusion
|
28 days after first infusion
|
|
Number of days alive off supplemental oxygen
Time Frame: 100 days after first infusion
|
100 days after first infusion
|
Collaborators and Investigators
Investigators
- Principal Investigator: David Ingbar, MD, Masonic Cancer Center, University of Minnesota
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
Other Study ID Numbers
- 2020LS075
- MT2020-12 (OTHER: University of Minnesota Masonic Cancer Center)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
China-Japan Friendship HospitalNot yet recruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
-
Dr. Behcet Uz Children's HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory Failure | Pediatric Acute Respiratory Distress Syndrome (PARDS)Turkey
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
-
Hospices Civils de LyonTerminatedAcute Respiratory Distress Syndrome (ARDS)France
Clinical Trials on Mesenchymal stromal cells
-
Leiden University Medical CenterCompletedRejection | Graft LossNetherlands
-
Postgraduate Institute of Medical Education and...UnknownRenal Transplant RejectionIndia
-
Mario Negri Institute for Pharmacological ResearchA.O. Ospedale Papa Giovanni XXIIITerminated
-
Karolinska InstitutetRegion StockholmTerminatedGraft-Versus-Host DiseaseSweden
-
Monia LoriniMario Negri Institute for Pharmacological ResearchUnknown
-
Guangzhou General Hospital of Guangzhou Military...First Affiliated Hospital, Sun Yat-Sen University; Guangzhou First People's... and other collaboratorsUnknownSevere Aplastic AnemiaChina
-
University of LiegeCentre Hospitalier Universitaire de LiegeRecruiting
-
Karolinska University HospitalKarolinska InstitutetUnknownAcute Respiratory Distress Syndrome, AdultSweden
-
Ettore Biagi, MDUnknownGraft vs Host DiseaseItaly
-
ShiCang YuXinqiao Hospital of ChongqingNot yet recruiting